according to the Globally Harmonized System



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

| Version | Revision Date: | SDS Number: |
|---------|----------------|-------------|
| 6.1 | 30.09.2023 | 59642-00027 |

Date of last issue: 04.04.2023 Date of first issue: 16.02.2015

1. PRODUCT AND COMPANY IDENTIFICATION

| Product name | : | Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation | | |
|---|-----|--|--|--|
| Manufacturer or supplier's de | eta | ils | | |
| Company | : | MSD | | |
| Address | : | Briahnager - Off Pune Nagar Road Wagholi - Pune - India 412 207 | | |
| Telephone | : | +1-908-740-4000 | | |
| Emergency telephone number | : | +1-908-423-6000 | | |
| E-mail address | : | EHSDATASTEWARD@msd.com | | |
| Recommended use of the chemical and restrictions on use | | | | |
| Recommended use Restrictions on use | : | Pharmaceutical Not applicable | | |

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

| Acute toxicity (Oral) | : | Category 5 |
|--|---|----------------------------------|
| Skin corrosion/irritation | : | Category 3 |
| Serious eye damage/eye irri- tation | : | Category 2A |
| Reproductive toxicity | : | Category 2 |
| Specific target organ toxicity - repeated exposure (Oral) | : | Category 2 (Blood, Bone, Kidney) |
| Short-term (acute) aquatic hazard | : | Category 3 |

GHS label elements

SAFETY DATA SHEET according to the Globally Harmonized System



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

| Version 6.1 | Revision Date: 30.09.2023 | SDS Number: 59642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 |
|----------------|------------------------------|---|---|
| Haza | rd pictograms | | |
| Signa | al word | : Warning | • |
| Haza | rd statements | H316 Causes H319 Causes H361d Suspe H373 May ca through prolo | e harmful if swallowed. s mild skin irritation. s serious eye irritation. ected of damaging the unborn child. use damage to organs (Blood, Bone, Kidney) unged or repeated exposure if swallowed. Il to aquatic life. |
| Preca | autionary statements | · Prevention: | |
| | | P260 Do not P264+P265 \ touch eyes. P273 Avoid re | read and follow all safety instructions before use. breathe dust. Wash hands thoroughly after handling. Do not elease to the environment. rotective gloves/ protective clothing/ eye protec- tection. |
| | | curs: Get me P305 + P351 for several m easy to do. C P318 IF expo | + P317 IF SWALLOWED or if skin irritation oc- dical help. + P338 IF IN EYES: Rinse cautiously with water inutes. Remove contact lenses, if present and continue rinsing. used or concerned, get medical advice. If eye irritation persists: Get medical help. |
| | | Storage: P405 Store Id | |
| | | Disposal: | e of contents/ container to an approved waste |

Other hazards which do not result in classification


May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|---------------|-------------|--------------------------|
| Cellulose | 9004-34-6 | >= 20 - < 30 |
| Lamivudine | 134678-17-4 | >= 10 - < 20 |
| Tenofovir | 202138-50-9 | >= 10 - < 20 |





Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

| Version 6.1 | Revision Date: 30.09.2023 | SDS Number: 59642-00027 | Date of last issue Date of first issue | | | | |
|----------------|--|--|---|-----------|--------------------|--|--|
| Dora | avirine | | 1338225-97-0 | | >= 5 - < 10 | | |
| 4. FIRST | AID MEASURES | | | | | | |
| Gen | eral advice | vice immedia | In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medica advice. | | | | |
| lf inh | naled | | nove to fresh air. | | | | |
| In ca | ase of skin contact | Remove cont Get medical a Wash clothin | ntact, immediately flush taminated clothing and attention. g before reuse. | shoes. | h plenty of water. | | |
| In ca | ase of eye contact | : In case of con for at least 15 If easy to do, | Thoroughly clean shoes before reuse. In case of contact, immediately flush eyes with plenty of wate for at least 15 minutes. If easy to do, remove contact lens, if worn. | | | | |
| lf sw | allowed | : If swallowed, Get medical a | Get medical attention. If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. | | | | |
| | t important symptoms effects, both acute and yed | : May be harm Causes mild Causes serio Suspected of May cause da | ful if swallowed. skin irritation. us eye irritation. damaging the unborn amage to organs throug | | ged or repeated | | |
| Prote | ection of first-aiders | : First Aid resp and use the r | exposure if swallowed. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). | | | | |
| Note | es to physician | : Treat sympto | matically and supportiv | ely. | , | | |
| 5. FIREF | IGHTING MEASURES | | | | | | |
| Suita | able extinguishing media | : Water spray Alcohol-resis Carbon dioxid Dry chemical | de (CO2) | | | | |
| Unsu med | uitable extinguishing | : None known. | | | | | |
| | cific hazards during fire- | concentration potential dust | ting dust; fine dust disp ns, and in the presence t explosion hazard. combustion products m | of an igr | ition source is a | | |
| Haza ucts | ardous combustion prod- | : Carbon oxide Nitrogen oxid Halogenated Metal oxides | les (NOx) | | | | |

Specific extinguishing meth- : Use extinguishing measures that are appropriate to local cir-

according to the Globally Harmonized System



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

| Vers 6.1 | sion | Revision Date: 30.09.2023 | | OS Number: 642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 |
|-------------|---|--|-----|---|---|
| | ods Special protective equipment for firefighters | | : | cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to so. Evacuate area. In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment. | |
| 6. A | CCIDE | NTAL RELEASE MEAS | SUF | RES | |
| | tive eq | al precautions, protec- uipment and emer- procedures | : | | ective equipment. ing advice (see section 7) and personal pro- recommendations (see section 8). |
| | Enviror | nmental precautions | : | Retain and dispos | akage or spillage if safe to do so. se of contaminated wash water. should be advised if significant spillages |
| | Methods and materials for containment and cleaning up | | : | tainer for disposal Avoid dispersal of with compressed Dust deposits sho es, as these may leased into the att Local or national u posal of this mate employed in the c mine which regula Sections 13 and 1 | dust in the air (i.e., clearing dust surfaces |

7. HANDLING AND STORAGE

| Technical measures | causing Provide | ectricity may accumulate and ignite suspended dust an explosion. adequate precautions, such as electrical grounding ding, or inert atmospheres. |
|-------------------------|----------------------|--|
| Local/Total ventilation | : Use only | with adequate ventilation. |
| Advice on safe handling | : Do not g | et on skin or clothing. |
| | Do not b | reathe dust. |
| | Do not s | wallow. |
| | Do not g | et in eyes. |
| | | in thoroughly after handling. |
| | Handle i | n accordance with good industrial hygiene and safety |
| | practice, sessmer | based on the results of the workplace exposure as- |
| | Minimize | e dust generation and accumulation. |
| | Keep co | ntainer closed when not in use. |
| | Keep aw | ay from heat and sources of ignition. |
| | | |



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

| Version 6.1 | Revision Date: 30.09.2023 | SDS Number: 59642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 | |
|-----------------------------|---------------------------|--|--|--|
| | | | onary measures against static discharges. prevent spills, waste and minimize release to the | |
| Conditions for safe storage | | Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations. | | |
| Mate | rials to avoid | | vith the following product types: | |

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

| Components | CAS-No. | Value type (Form of exposure) | Control parame- ters / Permissible concentration | Basis |
|------------|------------------|-------------------------------------|--|----------|
| Cellulose | 9004-34-6 | TWA | 10 mg/m3 | ACGIH |
| Lamivudine | 134678-17-4 | TWA | 100 µg/m3 (OEB 2) | Internal |
| Tenofovir | 202138-50-9 | TWA | 150 ug/m3 (OEB 2) | Internal |
| Doravirine | 1338225-97- 0 | TWA | 500 ug/m3 (OEB2) | Internal |

Components with workplace control parameters

| Engineering measures | : | Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. |
|-----------------------------|-----|---|
| Personal protective equipme | ent | |
| Respiratory protection | : | If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. |
| Filter type | : | Particulates type |
| Hand protection Material | | Chamical registerst alound |
| Material | • | Chemical-resistant gloves |
| Eye protection | : | Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. |
| Skin and body protection | : | Work uniform or laboratory coat. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of |

according to the Globally Harmonized System



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
|---------|----------------|-------------|---------------------------------|
| 6.1 | 30.09.2023 | 59642-00027 | Date of first issue: 16.02.2015 |

engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

| Appearance | : | powder |
|---|---|--|
| Colour | : | No data available |
| Odour | : | No data available |
| Odour Threshold | : | No data available |
| рН | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | Not applicable |
| Evaporation rate | : | Not applicable |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, han- dling or other means. |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | Not applicable |
| Relative vapour density | : | Not applicable |
| Relative density | : | No data available |
| Density | : | No data available |
| Solubility(ies) Water solubility | : | No data available |
| Partition coefficient: n- octanol/water | : | Not applicable |
| Auto-ignition temperature | : | No data available |
| Decomposition temperature | : | No data available |

according to the Globally Harmonized System



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

| Version 6.1 | Revision Date: 30.09.2023 | | S Number: 642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 |
|----------------|----------------------------|---|------------------------|---|
| | | | | |
| Visco Vis | sity scosity, kinematic | : | Not applicable | |
| Explo | sive properties | : | Not explosive | |
| Oxidi | zing properties | : | The substance of | r mixture is not classified as oxidizing. |
| Moleo | cular weight | : | No data available | e |
| Partic | cle size | : | No data available | e |

10. STABILITY AND REACTIVITY

| Reactivity Chemical stability Possibility of hazardous reac- tions | : : | |
|---|-----|---|
| Conditions to avoid | : | Heat, flames and sparks. Avoid dust formation. |
| Incompatible materials Hazardous decomposition | : | Oxidizing agents |
| products | | |

11. TOXICOLOGICAL INFORMATION

| Information on likely routes of exposure | : | Inhalation Skin contact Ingestion Eye contact |
|--|---|--|
| Acute toxicity | | |
| May be harmful if swallowed. | | |
| Product: | | |
| Acute oral toxicity | : | Acute toxicity estimate: 2,605 mg/kg Method: Calculation method |
| Components: | | |
| Cellulose: | | |
| Acute oral toxicity | : | LD50 (Rat): > 5,000 mg/kg |
| Acute inhalation toxicity | : | LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist |
| Acute dermal toxicity | : | LD50 (Rabbit): > 2,000 mg/kg |

according to the Globally Harmonized System



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

| rsion | Revision Date: 30.09.2023 | | 0S Number: 642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 |
|------------------|--------------------------------------|---|--|---|
| | | | | |
| Lamiv | vudine: | | | |
| Acute | oral toxicity | : | LD50 (Rat): > 2,0 | 00 mg/kg |
| | | | LD50 (Mouse): 4, Remarks: No mor | 000 mg/kg tality observed at this dose. |
| | toxicity (other routes of istration) | : | LD50 (Rat): > 2,0 Application Route | |
| Tenof | ovir: | | | |
| Acute | oral toxicity | : | LD50 (Rat): > 1,5 | 00 mg/kg |
| | | | LD50 (Dog): 30 m | ng/kg |
| Dorav | irine: | | | |
| Acute | oral toxicity | : | LD50 (Rat): > 750 Remarks: No mor |) mg/kg tality observed at this dose. |
| | | | (Rat): Method: Pl Remarks: No evic | nototoxicity lence of phototoxicity was observed |
| | | | LD50 (Dog): > 1,0 Remarks: No mor | 000 mg/kg tality observed at this dose. |
| | | | LD50 (Mouse): > Remarks: No mor | 450 mg/kg tality observed at this dose. |
| Skin o | corrosion/irritation | | | |
| Cause | es mild skin irritation. | | | |
| Comp | onents: | | | |
| Lamiv | vudine: | | | |
| Specie Result | | : | Rabbit Mild skin irritation | |
| Tenof | ovir: | | | |
| Specie Result | | : | Rabbit Mild skin irritation | |
| Dorav | virine: | | | |
| _ | rks | | No data available | |

Serious eye damage/eye irritation

Causes serious eye irritation.

according to the Globally Harmonized System



| ersion 1 | Revision Date: 30.09.2023 | SDS Number: 59642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 |
|----------------|--|---------------------------------------|---|
| Com | oonents: | | |
| Lami | vudine: | | |
| Speci | | : Rabbit | |
| Resu | | : No eye irritation | |
| Teno | fovir: | | |
| Speci | | : Rabbit | |
| Resu | lt | : Severe irritation | |
| | virine: | | |
| Rema | arks | : No data availab | le |
| Resp | iratory or skin sens | itisation | |
| | sensitisation | | |
| Not c | assified based on av | ailable information. | |
| - | iratory sensitisatior lassified based on av | | |
| | oonents: | | |
| Lami | vudine: | | |
| Expo | sure routes | : Dermal | |
| Speci | | : Guinea pig | |
| Resu | lt | : Not a skin sensi | tizer. |
| Teno | - | | |
| Test | | : Maximisation Te | est |
| Expos Speci | sure routes es | : Skin contact : Guinea pig | |
| Resu | | : Not a skin sensi | tizer. |
| Dora | virine: | | |
| Rema | arks | : No data availab | le |
| Germ | cell mutagenicity | | |
| Not c | lassified based on av | ailable information. | |
| <u>Com</u> | oonents: | | |
| Cellu | lose: | | |
| Geno | toxicity in vitro | : Test Type: Bact Result: negative | erial reverse mutation assay (AMES) |
| | | Test Type: In vit Result: negative | ro mammalian cell gene mutation test |
| Gono | toxicity in vivo | · Test Type: Mar | nmalian erythrocyte micronucleus test (in v |

according to the Globally Harmonized System



| cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative Cenotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Mouse Lymphoma Result: equivocal Genotoxicity in vivo : Test Type: Micronucleus test Species: Rat Application Route: Oral Result: negative Test Type: Unscheduled DNA synthesis (UDS) test w mammalian liver cells in vivo Species: Rat Result: negative Tenofovir: Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Tenofovir: Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Genotoxicity in vivo : Test Type: Nutagenicity (in vivo mammalian bone-ma cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Intraperitoneal injection Result: negative Gern cell mutagenicity - : Weight of evidence does not support classification as cell mutagen. | Version 6.1 | Revision Date: 30.09.2023 | SDS Number: 59642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 |
|---|----------------|---------------------------|-----------------------------|---|
| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Genotoxicity in vivo : Test Type: Micronucleus test Species: Rat Application Route: Oral Result: negative Genotoxicity in vivo : Test Type: Unscheduled DNA synthesis (UDS) test w mammalian liver cells in vivo Species: Rat Result: negative Tenofovir: : Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Tenofovir: : Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation tes Result: positive Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-ma cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Intraperitoneal injection Result: negative Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as cell mutagen. Doravirine: : Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosomal aberration rest system: Chinese hamster ovary cells Result: negative Genotoxicity in vitro : Test Type: Micronucleus test Species: Rat | | | Species: M Application | ouse Route: Ingestion |
| Genotoxicity in vivo : Test Type: Mouse Lymphoma Result: equivocal Genotoxicity in vivo : Test Type: Micronucleus test Species: Rat Application Route: Oral Result: negative Test Type: Unscheduled DNA synthesis (UDS) test w mammalian liver cells in vivo Species: Rat Result: negative Tenofovir: Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: equivocal Test Type: In vitro mammalian cell gene mutation tes Result: positive Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-ma cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Intraperitoneal injection Result: negative Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as cell mutagen. Doravirine: : Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative Genotoxicity in vitro : Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative Genotoxicity in vitro : Test Type: Micronucleus test Species: Rat | | | | |
| Species: Rat Application Route: Oral Result: negative Test Type: Unscheduled DNA synthesis (UDS) test w mammalian liver cells in vivo Species: Rat Result: negative Tenofovir: Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: equivocal Test Type: In vitro mammalian cell gene mutation tes Result: positive Genotoxicity in vivo : : Test Type: Mutagenicity (in vivo mammalian bone-ma cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Intraperitoneal injection Result: negative Germ cell mutagenicity - Assessment : Doravirine: : Genotoxicity in vitro : : Test Type: Bacterial reverse mutation assay (AMES) Result: negative : Weight of evidence does not support classification as cell mutagen. : : : : : : : : : : : : : : : : : : : : : : : : : : : | | | Test Type: | Mouse Lymphoma |
| mammalian liver cells in vivo Species: Rat Result: negative Tenofovir: Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: equivocal Test Type: In vitro mammalian cell gene mutation tes Result: positive Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-macytogenetic test, chromosomal analysis) Species: Mouse Application Route: Intraperitoneal injection Result: negative Germ cell mutagenicity - Assessment Doravirine: Genotoxicity in vitro Sectorizity in vitro Sectorizity in vitro Sectorizity in vitro Sectorizity in vitro Result: negative Genotoxicity in vitro Sectorizity in vitro Sectorizity in vitro Result: negative Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative Genotoxicity in vivo Itest Type: Micronucleus test Species: Rat | Geno | toxicity in vivo | Species: Ra Application | at Route: Oral |
| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: equivocal Test Type: In vitro mammalian cell gene mutation tes Result: positive Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-ma cytogenetic test, chromosomal analysis) Species: Mouse Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as cell mutagen. Doravirine: : Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Doravirine: : Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Genotoxicity in vitro : Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative Genotoxicity in vivo : Test Type: Micronucleus test Species: Rat | | | mammalian Species: Ra | at liver cells in vivo |
| Result: equivocal Test Type: In vitro mammalian cell gene mutation tes Result: positive Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-macytogenetic test, chromosomal analysis) Species: Mouse Application Route: Intraperitoneal injection Result: negative : Weight of evidence does not support classification as cell mutagen. Doravirine: Genotoxicity in vitro : : Test Type: Bacterial reverse mutation assay (AMES) Result: negative : Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative : Test Type: Micronucleus test Species: Rat | Teno | fovir: | | |
| Result: positive Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-macytogenetic test, chromosomal analysis) Species: Mouse Application Route: Intraperitoneal injection Result: negative Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as cell mutagen. Doravirine: : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Genotoxicity in vitro : Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative Genotoxicity in vivo : Test Type: Micronucleus test Species: Rat | Geno | toxicity in vitro | | |
| cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Intraperitoneal injection Result: negativeGerm cell mutagenicity - Assessment:Weight of evidence does not support classification as cell mutagen.Doravirine: Genotoxicity in vitro:Test Type: Bacterial reverse mutation assay (AMES) Result: negativeTest Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative:Genotoxicity in vivo:Test Type: Micronucleus test Species: Rat | | | | |
| Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as cell mutagen. Doravirine: Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative Genotoxicity in vivo : Test Type: Micronucleus test Species: Rat | Geno | toxicity in vivo | cytogenetic Species: M | test, chromosomal analysis) ouse |
| Assessment cell mutagen. Doravirine: Genotoxicity in vitro Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative Genotoxicity in vivo : Test Type: Micronucleus test Species: Rat | | | | |
| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative Genotoxicity in vivo : Test Type: Micronucleus test Species: Rat | | . . | • | |
| Result: negative Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative Genotoxicity in vivo : Test Type: Micronucleus test Species: Rat | Dora | virine: | | |
| Genotoxicity in vivo : Test Type: Micronucleus test Species: Rat | Geno | toxicity in vitro | | |
| Species: Rat | | | Test system | n: Chinese hamster ovary cells |
| Cell type: Bone marrow Application Route: Oral | Geno | toxicity in vivo | Species: Ra Cell type: B | at Sone marrow |

according to the Globally Harmonized System



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

| Version | Revisio |
|---------|---------|
| 6.1 | 30.09.2 |

on Date: 2023 SDS Number: 59642-00027 Date of last issue: 04.04.2023 Date of first issue: 16.02.2015

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

| Species Application Route Exposure time Result | : Rat : Ingestion : 72 weeks : negative |
|---|--|
| Lamivudine: | |
| Species | : Rat : 2 Years |
| Exposure time Result | : negative |
| Result | . negative |
| Species | : Mouse |
| Exposure time | : 2 Years |
| Result | : negative |
| | |
| Tenofovir: | |
| Species | : Mouse |
| Application Route | : Oral |
| Exposure time | : 104 weeks |
| Result | : negative |
| Species | : Rat |
| Application Route | : Oral |
| Exposure time | : 104 weeks |
| Result | : negative |
| | |
| Doravirine: | |
| Species | : Mouse |
| Application Route | : Oral |
| Exposure time | : 6 Months |
| Result | : negative |
| Remarks | : No significant adverse effects were reported |

Reproductive toxicity

Suspected of damaging the unborn child.

:

Components:

Cellulose:

Effects on fertility

Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion

according to the Globally Harmonized System



| Version 6.1 | Revision Date: 30.09.2023 | SDS Number: 59642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 |
|----------------|---------------------------------|--|---|
| Effect ment | ts on foetal develop- | Species: Rat | ertility/early embryonic development |
| | | Application F Result: nega | Route: Ingestion tive |
| Lami | vudine: | | |
| Effect | ts on fertility | Species: Rat Application F Fertility: NO | Route: Oral AEL: 900 mg/kg body weight ffects on fertility and early embryonic develop- |
| Effect ment | ts on foetal develop- | Species: Ral Application F Symptoms: F | Route: Oral Preimplantation loss, Skeletal malformations ryotoxic effects and adverse effects on the off- |
| | | Species: Rat Application F Developmen | Route: Oral tal Toxicity: LOAEL: 45 mg/kg body weight Effects on foetal development |
| Repro sessn | oductive toxicity - As- nent | : Some evider animal expe | nce of adverse effects on development, based on riments. |
| Teno | fovir: | | |
| Effect | ts on fertility | Species: Rat Application F | |
| Effect ment | ts on foetal develop- | Species: Rat Application F | |
| | | Species: Ral | mbryo-foetal development bbit dverse effects |
| Dora | virine: | | |
| Effect | ts on fertility | | ertility t, male and female AEL: 450 mg/kg body weight |
| | | 12 / | 20 |

SAFETY DATA SHEET according to the Globally Harmonized System



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

| Version 6.1 | Revision Date: 30.09.2023 | SDS Number: 59642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 |
|----------------|------------------------------|--|---|
| | ts on foetal develop- | | ects on fertility bryo-foetal development |
| ment | | Species: Rat Application Ro Developmenta Result: No adv | I Toxicity: NOAEL: 450 mg/kg body weight |
| | | Species: Rabb Application Ro | ute: Oral I Toxicity: NOAEL: 300 mg/kg body weight |
| STOT | - single exposure | | |

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Blood, Bone, Kidney) through prolonged or repeated exposure if swallowed.

Components:

Lamivudine:

| Exposure routes Target Organs Assessment | : | Ingestion Blood May cause damage to organs through prolonged or repeated exposure. |
|--|---|---|
| Tenofovir: | | |

| Target Organs Assessment | : | Bone, Kidney May cause damage to organs through prolonged or repeated |
|-----------------------------|---|--|
| | | exposure. |

Repeated dose toxicity

Components:

Cellulose:

| Species | : | Rat |
|-------------------|---|----------------|
| NOAEL | : | >= 9,000 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 90 Days |

Lamivudine:

| Species | : | Rat |
|-------------------|---|---|
| NOAEL | : | 425 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 6 Months |
| Target Organs | : | Blood |
| Symptoms | : | Gastrointestinal discomfort, Breathing difficulties, Fatality |

according to the Globally Harmonized System




| Version 6.1 | Revision Date: 30.09.2023 | SDS Number: 59642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 |
|-------------------------------------|---|---|--|
| | | | |
| Rem | arks | : Significant to | xicity observed in testing |
| Expo Targ | | | n, Liver arrhoea, Changes in the blood count, Liver dis- ointestinal disturbance |
| Expo | | : Mouse : 500 mg/kg : Oral : 1 Months : Blood | |
| Spec NOA LOA Appli Expo | EL | : Rat : 30 mg/kg : 300 mg/kg : Oral : 13 Weeks : Bone | |
| Expo | EL | : Dog : 3 mg/kg : >= 10 mg/kg : Oral : 42 Weeks : Kidney | |
| Expo | | : Monkey : 10 mg/kg : Subcutaneou : 10 Months : Bone | IS |
| Dora | virine: | | |
| Spec NOA Appli | ties EL Ication Route Isure time | : Rat : 450 mg/kg : Oral : 6 Months : No significan | t adverse effects were reported |
| | EL cation Route sure time | : Mouse : > 450 mg/kg : Oral : 3 Months : No significan | t adverse effects were reported |
| Spec | ies | : Dog | |
| | | | |

according to the Globally Harmonized System



| ersion 1 | Revision Date: 30.09.2023 | | 0S Number: 642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 |
|------------------|---|-------|--|---|
| | ation Route sure time | : : : | > 1,000 mg/kg Oral 9 Months No significant ad | verse effects were reported |
| - | ation toxicity assified based on availa | able | information. | |
| Expe | rience with human exp | osi | ıre | |
| Comp | oonents: | | | |
| Lamiv | /udine: | | | |
| Ingest | tion | : | Symptoms: Head rhoea, Cough | dache, Fatigue, Respiratory disorders, Diar- |
| Tenof | ovir: | | | |
| Ingest | tion | : | Symptoms: Naus ache, Rash | sea, Diarrhoea, Vomiting, flatulence, Head- |
| Dora | | | | |
| Ingest | lion | : | | usion, Headache, Dizziness, Nausea, Rash s, flushing, Neurological disorders, mental |
| . ECOLO | OGICAL INFORMATION | N | | |
| Ecoto | oxicity | | | |
| Comp | oonents: | | | |
| Cellu | ose: | | | |
| | ty to fish | : | Exposure time: 4 | tipes (Japanese medaka)): > 100 mg/l 8 h on data from similar materials |
| Lamiv | /udine: | | | |
| | ty to fish | : | Exposure time: 9 | es promelas (fathead minnow)): > 97.7 mg/l 96 h Fest Guideline 203 |
| | ty to daphnia and other ic invertebrates | : | Exposure time: 4 | magna (Water flea)): > 100 mg/l 8 h Fest Guideline 202 |
| Toxici plants | ty to algae/aquatic | : | mg/l Exposure time: 7 | irchneriella subcapitata (green algae)): > 96 '2 h Fest Guideline 201 |
| | | | NOEC (Pseudol mg/l | kirchneriella subcapitata (green algae)): 96. |






| Version 6.1 | Revision Date: 30.09.2023 | - | 0S Number: 642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 |
|----------------|--|---|---|---|
| | | | Exposure time: 72 Method: OECD Te | |
| Ten | ofovir: | | | |
| | icity to algae/aquatic | : | EC50 (Raphidoce mg/l End point: Growth Exposure time: 72 Method: OECD To | 2 h |
| | | | NOEC (Raphidoo mg/l Exposure time: 72 Method: OECD Te | |
| Тох | icity to microorganisms | : | EC50: > 1,000 mg Exposure time: 3 Test Type: Respir Method: OECD Te | h ation inhibition |
| | | | NOEC: > 1,000 m Exposure time: 3 Test Type: Respir Method: OECD Te | h ation inhibition |
| Tox icity | icity to fish (Chronic tox-) | : | NOEC: 9 mg/l Exposure time: 32 Species: Pimepha Method: OECD Te | ales promelas (fathead minnow) |
| aqu | icity to daphnia and other atic invertebrates (Chron- oxicity) | : | NOEC: 12 mg/l Exposure time: 21 Species: Daphnia Method: OECD To | magna (Water flea) |
| Dor | avirine: | | | |
| | icity to daphnia and other atic invertebrates | : | Exposure time: 48 Method: OECD Te | |
| | | | EC50 (Americamy Exposure time: 96 | |
| Tox plar | icity to algae/aquatic nts | : | mg/l Exposure time: 72 Method: OECD To | |
| | | | NOEC (Pseudoki | rchneriella subcapitata (green algae)): 5.8 |



according to the Globally Harmonized System

| Vers 6.1 | ion | Revision Date: 30.09.2023 | | S Number: 642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 |
|-------------|----------------------------|---|----|--|---|
| | | | | mg/I Exposure time: 72 Method: OECD Te Remarks: No toxic | |
| | Toxicity | to microorganisms | : | EC50: > 1,000 mg Exposure time: 3 l Test Type: Respire Method: OECD Te | n ation inhibition |
| | | | | NOEC: 1,000 mg/ Exposure time: 3 I Test Type: Respire Method: OECD Te | n ation inhibition |
| | Toxicity icity) | to fish (Chronic tox- | : | Method: OECD Te | les promelas (fathead minnow) |
| | | to daphnia and other invertebrates (Chron- y) | : | Method: OECD Te | magna (Water flea) |
| | Persiste | ence and degradabili | ty | | |
| | <u>Compo</u> | nents: | | | |
| | Cellulo: Biodegra | se: adability | : | Result: Readily bio | odegradable. |
| | Lamivu Biodegra | dine: adability | : | Result: Not readily Biodegradation: 4 Exposure time: 28 | · % |
| | Tenofov Biodegra | vir: adability | : | Result: Not readily Biodegradation: 3 Exposure time: 28 Method: OECD Te | 8.66 % 5 d |
| | Doravir Biodegra | ine: adability | : | Result: Not readily Biodegradation: 2 Exposure time: 28 | 2 % |





Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

| Versio 6.1 | n Revision Date: 30.09.2023 | | 0S Number: 642-00027 | Date of last issue: 04.04.2023 Date of first issue: 16.02.2015 |
|---------------|--|----|--|---|
| В | ioaccumulative potential | | | |
| | omponents: | | | |
| | amivudine: | | | |
| P | artition coefficient: n- ctanol/water | : | log Pow: -1.44 | |
| Т | enofovir: | | | |
| | artition coefficient: n- ctanol/water | : | log Pow: 1.06 pH: 7 | |
| D | oravirine: | | | |
| | artition coefficient: n- ctanol/water | : | log Pow: 2.08 | |
| М | lobility in soil | | | |
| <u>C</u> | omponents: | | | |
| Li | amivudine: | | | |
| | istribution among environ- ental compartments | : | log Koc: 2.03 | |
| Т | enofovir: | | | |
| | istribution among environ- ental compartments | : | log Koc: 3.33 Method: OECD T | est Guideline 106 |
| D | oravirine: | | | |
| | istribution among environ- ental compartments | : | log Koc: 2.86 | |
| - | ther adverse effects o data available | | | |
| 13. DI | SPOSAL CONSIDERATION | NS | | |
| | | | | |
| | isposal methods | | _ | |
| W | laste from residues | : | | waste into sewer. ordance with local regulations. |
| С | ontaminated packaging | : | Empty containers dling site for recyc | should be taken to an approved waste han- |

14. TRANSPORT INFORMATION

International Regulations





Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

| Version | Revision Date: |
|---------|-----------------------|
| 6.1 | 30.09.2023 |

SDS Number: 59642-00027

Date of last issue: 04.04.2023 Date of first issue: 16.02.2015

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

| AICS | : not determined |
|-------|------------------|
| DSL | : not determined |
| IECSC | : not determined |

16. OTHER INFORMATION

| Revision Date | : | 30.09.2023 |
|---|-----|--|
| Further information | | |
| Sources of key data used to compile the Safety Data Sheet | : | Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/ |
| Date format | : | dd.mm.yyyy |
| Full text of other abbreviation | ons | |
| ACGIH | : | USA. ACGIH Threshold Limit Values (TLV) |
| ACGIH / TWA | : | 8-hour, time-weighted average |

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

| Version | Revision Date: | SDS Number: | Date of last issue: 04.04.2023 |
|---------|----------------|-------------|---------------------------------|
| 6.1 | 30.09.2023 | 59642-00027 | Date of first issue: 16.02.2015 |

Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN